Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan » 05:29 02/24/21 02/24 05:29 02/24/21 05:29 TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) , NVAX Novavax $243.21 / -2.2 (-0.90%) , MRNA Moderna $150.02 / -9.27 (-5.82%) Takeda Pharmaceutical… Takeda Pharmaceutical (TAK) announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax's (NVAX) COVID-19 vaccine candidate in Japan. Earlier this month, Takeda completed enrollment in the company's Phase 1/2 immunogenicity and safety study of Moderna's (MRNA) COVID-19 vaccine candidate in Japan. Takeda previously announced its commitment to providing access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. Takeda will receive a manufacturing technology transfer from Novavax and will be responsible for the development and commercialization based on manufacturing capacity of over 250M doses of TAK-019. The company will also import and distribute 50M doses of TAK-919 as part of a joint partnership with Moderna and the Government of Japan's Ministry of Health Labour and Welfare, or MHLW. Results from the TAK-919 study are expected in the first half of 2021 and results from the TAK-019 study in the second half of 2021. Once available, the study results will be submitted to the Japan Pharmaceuticals and Medical Devices Agency, or PMDA, as part of the NDA filing process. Pending regulatory approval, Takeda intends to start distributing TAK-919 in the first half of 2021 and aims to start distributing TAK-019 in late 2021. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TAK NVAX MRNA TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) 02/12/21 Takeda Pharmaceutical's maribavir Phase 3 clinical trial met primary endpoint 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine NVAX Novavax $243.21 / -2.2 (-0.90%) 02/22/21 House committee posts remarks from Pfizer, Moderna, J&J execs ahead of testimony 02/22/21 Novavax completes enrollment of PREVENT-19 Phase 3 trial 02/18/21 Novavax enters MOU with Gavi to provide 1.1B vaccine doses for COVAX facility 02/16/21 Novavax, SK Bioscience expand collaboration and license agreement MRNA Moderna $150.02 / -9.27 (-5.82%) 02/22/21 Moderna says CDC gave 'positive feedback' on boosting vaccine supply in vials 02/22/21 Amyris announces pre-clinical results for COVID RNA vaccine platform 02/17/21 European Commission purchases additional 150 doses of Moderna COVID-19 vaccine TAK NVAX MRNA TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital NVAX Novavax $243.21 / -2.2 (-0.90%) 02/23/21 B. Riley Securities B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/22/21 Cantor Fitzgerald Cantor says PREVENT-19 gives Novavax potential for differentiated analyses 02/22/21 B. Riley Securities B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up 02/18/21 B. Riley Securities Novavax price target raised to $397 from $334 at B. Riley Securities MRNA Moderna $150.02 / -9.27 (-5.82%) 02/18/21 Jefferies Moderna price target raised to $180 from $150 at Jefferies 02/18/21 Morgan Stanley Moderna price target raised to $215 from $150 at Morgan Stanley 02/17/21 Piper Sandler Moderna price target raised to $208 from $170 at Piper Sandler 02/03/21 Piper Sandler Moderna's vaccine approved in Singapore, says Piper Sandler NVAX MRNA NVAX Novavax $243.21 / -2.2 (-0.90%) 11/09/20 Novavax reports Q3 EPS ($3.21), may not compare to consensus $1.73 MRNA Moderna $150.02 / -9.27 (-5.82%) 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 19 May TAK NVAX MRNA TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports NVAX Novavax $243.21 / -2.2 (-0.90%) 02/11/21 EU official tells Reuters Novavax vaccine deal is close 01/29/21 Novavax expects to make 150M vaccine doses per month by May/June, Reuters says 01/11/21 EU close to 200M dose deal with Novavax, Moderna talks ongoing, Reuters reports 11/04/20 Novovax, Pfizer secure vaccine agreements with Australia, SMH reports MRNA Moderna $150.02 / -9.27 (-5.82%) 02/17/21 Moderna to supply EU with another 150M vaccine doses in 2021, FT reports 02/12/21 FDA tells Moderna it can boost vaccine supply in each vial, NY Times reports 02/11/21 White House secures deals for additional 200M COVID-19 vaccine doses, CNBC says 02/11/21 Biden to announce deals for another 200M vaccine doses, Washington Post says TAK NVAX MRNA TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers NVAX Novavax $243.21 / -2.2 (-0.90%) 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday MRNA Moderna $150.02 / -9.27 (-5.82%) 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories at midday 02/23/21 10th Annual Global Healthcare Virtual Conference 03/01/21 41st Annual Healthcare Virtual Conference 02/25/21 Moderna - MRNA 03/01/21 Novavax - NVAX TAK NVAX MRNA TAK Takeda Pharmaceutical $17.15 / -0.15 (-0.87%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish NVAX Novavax $243.21 / -2.2 (-0.90%) 02/22/21 Million dollar long-shot call spread buyer in Noravax will cross earnings 11/27/20 Unusually active option classes on open November 27th 11/13/20 Novavax call volume above normal and directionally bullish 11/12/20 Novavax call volume above normal and directionally bullish MRNA Moderna $150.02 / -9.27 (-5.82%) 02/01/21 Moderna call volume above normal and directionally bullish 01/25/21 Moderna call volume above normal and directionally bullish 12/17/20 Moderna call volume above normal and directionally bullish 11/27/20 Moderna call buyer realizes 22% same-day gains

Over a week ago
Initiation	Phathom Pharmaceuticals initiated with an Outperform at BMO Capital » 06:11 02/17/21 02/17 06:11 02/17/21 06:11 PHAT Phathom Pharmaceuticals $42.86 / -2.11 (-4.69%) BMO Capital analyst Gary… BMO Capital analyst Gary Nachman initiated coverage of Phathom Pharmaceuticals with an Outperform rating and $63 price target. The stock is an "exciting pure-play" in gastroenterology offering major catalysts this year that include the Vonoprazan Phase 3 data for H. Pylori Q2 and gastroesophageal reflux disorder in the second half of 2021, the analyst tells investors in a research note, adding that these could show meaningful improvement over standard-of-care. ShowHide Related Items >><< Company News Street Research Earnings Syndicate PHAT Phathom Pharmaceuticals $42.86 / -2.11 (-4.69%) 01/19/21 Phathom Pharmaceuticals completes enrollment in Phase 3 H. pylori trial 12/14/20 Phathom plans to initiate vonoprazan development program in NERD 11/30/20 Phathom completes patient enrollment in erosive esophagitis trial PHAT Phathom Pharmaceuticals $42.86 / -2.11 (-4.69%) 02/02/21 Guggenheim Phathom Pharmaceuticals initiated with a Buy at Guggenheim 01/28/21 Fly Intel: Top five analyst initiations 01/28/21 JonesTrading Phathom Pharmaceuticals initiated with a Buy at JonesTrading 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 PHAT Phathom Pharmaceuticals $42.86 / -2.11 (-4.69%) 11/10/20 Phathom Pharmaceuticals reports Q3 EPS ($1.02), consensus (67c) 17 Dec
Hot Stocks	Takeda Pharmaceutical's maribavir Phase 3 clinical trial met primary endpoint » 06:03 02/12/21 02/12 06:03 02/12/21 06:03 TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) Takeda Pharmaceutical… Takeda Pharmaceutical announced new, late-breaking Phase 3 data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir) which met its primary endpoint of superiority compared to conventional antiviral therapies, one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients with refractory, with or without resistance, cytomegalovirus infection/disease. Overall, more than twice as many transplant recipients with R/R CMV infection/disease treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8, the study's primary endpoint, as compared to 23.9% of those on conventional antiviral therapies. The study's key secondary endpoint was met by demonstrating maribavir's improvement over conventional therapies in clearance of CMV viremia and associated symptom control maintained through Study Week 16. Transplant recipients receiving maribavir exhibited lower incidence of treatment-related toxicities common with conventional antiviral therapies. Those receiving maribavir experienced lower rates of treatment-related neutropenia vs. valganciclovir/ganciclovir and acute kidney injury vs. foscarnet. Any treatment-emergent adverse events were 97.4 for maribavir and 91.4% for the conventional therapy group. TEAEs leading to study drug discontinuation were 13.2% in the maribavir group and 31.9% in the conventional therapy group. Two treatment-related serious TEAEs led to death. ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Events Options TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers 03/01/21 41st Annual Healthcare Virtual Conference TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/12/21 02/12 04:55 02/12/21 04:55 ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) , AVRO Avrobio $16.85 / +0.05 (+0.30%) , BMRN BioMarin $86.80 / +1.37 (+1.60%) , DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) , FIXX Homology Medicines $13.75 / -0.24 (-1.72%) , FOLD Amicus $18.73 / -0.86 (-4.39%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $51.13 / -0.91 (-1.75%) , ORPH Orphazyme $12.79 / -0.01 (-0.08%) , ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) , PASG Passage Bio $21.44 / +1.465 (+7.33%) , PFE Pfizer $34.43 / -0.31 (-0.89%) , RARE Ultragenyx $162.86 / -4.38 (-2.62%) , SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) , SNY Sanofi $47.68 / -0.375 (-0.78%) , TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) , TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig SNY Sanofi $47.68 / -0.375 (-0.78%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 PFE Pfizer $34.43 / -0.31 (-0.89%) 02/10/21 BioNTech provides update on vaccine production at Marburg manufacturing site 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B PASG Passage Bio $21.44 / +1.465 (+7.33%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $12.79 / -0.01 (-0.08%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $51.13 / -0.91 (-1.75%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending 02/08/21 Amicus announces preclinical Fabry disease gene therapy data FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $86.80 / +1.37 (+1.60%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $16.85 / +0.05 (+0.30%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $86.80 / +1.37 (+1.60%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 02/10/21 Fly Intel: Top five analyst upgrades 02/10/21 Cantor Fitzgerald Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $18.73 / -0.86 (-4.39%) 02/12/21 Cantor Fitzgerald Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald 02/12/21 JPMorgan Amicus downgraded to Neutral from Overweight at JPMorgan 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen IDRSF Idorsia $0.00 / + (+0.00%) 02/10/21 Morgan Stanley Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan NVTA Invitae $51.13 / -0.91 (-1.75%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $12.79 / -0.01 (-0.08%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $21.44 / +1.465 (+7.33%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.43 / -0.31 (-0.89%) 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/11/21 Piper Sandler Ultragenyx price target raised to $170 from $165 at Piper Sandler 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $47.68 / -0.375 (-0.78%) 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $47.68 / -0.375 (-0.78%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx reports Q4 EPS (37c), consensus ($1.16) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.43 / -0.31 (-0.89%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $21.44 / +1.465 (+7.33%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $51.13 / -0.91 (-1.75%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $18.73 / -0.86 (-4.39%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $86.80 / +1.37 (+1.60%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 12 Feb 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $47.68 / -0.375 (-0.78%) 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says PFE Pfizer $34.43 / -0.31 (-0.89%) 02/11/21 White House secures deals for additional 200M COVID-19 vaccine doses, CNBC says 02/11/21 Biden to announce deals for another 200M vaccine doses, Washington Post says 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says FOLD Amicus $18.73 / -0.86 (-4.39%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $86.80 / +1.37 (+1.60%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $47.68 / -0.375 (-0.78%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.43 / -0.31 (-0.89%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $21.44 / +1.465 (+7.33%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $12.79 / -0.01 (-0.08%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $51.13 / -0.91 (-1.75%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $86.80 / +1.37 (+1.60%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/16/21 Abeona Clinical Investigator Webinar 02/23/21 10th Annual Global Healthcare Virtual Conference 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.43 / -0.31 (-0.89%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $21.44 / +1.465 (+7.33%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $51.13 / -0.91 (-1.75%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $86.80 / +1.37 (+1.60%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/11/21 02/11 04:55 02/11/21 04:55 ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) , AVRO Avrobio $16.80 / -0.88 (-4.98%) , BMRN BioMarin $85.43 / -0.31 (-0.36%) , DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) , FIXX Homology Medicines $14.00 / -0.36 (-2.51%) , FOLD Amicus $19.59 / +0.41 (+2.14%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $51.98 / -0.57 (-1.08%) , ORPH Orphazyme $12.79 / -0.28 (-2.14%) , ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) , PASG Passage Bio $19.87 / -0.22 (-1.10%) , PFE Pfizer $34.74 / -0.22 (-0.63%) , RARE Ultragenyx $167.17 / -0.19 (-0.11%) , SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) , SNY Sanofi $48.06 / -0.815 (-1.67%) , TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) , TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig SNY Sanofi $48.06 / -0.815 (-1.67%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $167.17 / -0.19 (-0.11%) 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 PFE Pfizer $34.74 / -0.22 (-0.63%) 02/10/21 BioNTech provides update on vaccine production at Marburg manufacturing site 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B PASG Passage Bio $19.87 / -0.22 (-1.10%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $12.79 / -0.28 (-2.14%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $51.98 / -0.57 (-1.08%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.59 / +0.41 (+2.14%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $85.43 / -0.31 (-0.36%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $16.80 / -0.88 (-4.98%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $85.43 / -0.31 (-0.36%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 02/10/21 Fly Intel: Top five analyst upgrades 02/10/21 Cantor Fitzgerald Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.59 / +0.41 (+2.14%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/10/21 Morgan Stanley Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan NVTA Invitae $51.98 / -0.57 (-1.08%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $12.79 / -0.28 (-2.14%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $19.87 / -0.22 (-1.10%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.74 / -0.22 (-0.63%) 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink RARE Ultragenyx $167.17 / -0.19 (-0.11%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.06 / -0.815 (-1.67%) 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.06 / -0.815 (-1.67%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $167.17 / -0.19 (-0.11%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.74 / -0.22 (-0.63%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $19.87 / -0.22 (-1.10%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $51.98 / -0.57 (-1.08%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.59 / +0.41 (+2.14%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $85.43 / -0.31 (-0.36%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 12 Feb 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.06 / -0.815 (-1.67%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.74 / -0.22 (-0.63%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.59 / +0.41 (+2.14%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $85.43 / -0.31 (-0.36%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.06 / -0.815 (-1.67%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.74 / -0.22 (-0.63%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $19.87 / -0.22 (-1.10%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $12.79 / -0.28 (-2.14%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $51.98 / -0.57 (-1.08%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.59 / +0.41 (+2.14%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $85.43 / -0.31 (-0.36%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/16/21 Abeona Clinical Investigator Webinar 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.74 / -0.22 (-0.63%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $19.87 / -0.22 (-1.10%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $51.98 / -0.57 (-1.08%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.59 / +0.41 (+2.14%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $85.43 / -0.31 (-0.36%) 09/18/20 BioMarin call volume above normal and directionally bullish

Hot Stocks	Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan » 05:30 02/10/21 02/10 05:30 02/10/21 05:30 TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) Takeda Pharmaceutical… Takeda Pharmaceutical announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, or CD. The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel. Study Darvadstrocel-3002 is a Phase 3, multicenter, open-label, uncontrolled study investigating the efficacy and safety of darvadstrocel for the treatment of complex perianal fistulas in 22 Japanese adult patients with non-active/mildly active luminal CD. Results from Study Darvadstrocel-3002 will be presented at a scientific meeting in the near future. ADMIRE-CD was a randomized, double-blind, controlled, Phase 3 trial investigating the efficacy and safety of darvadstrocel for the treatment of complex perianal fistulas in 212 adult patients with non-active/mildly active luminal CD. ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Events Options TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers 03/01/21 41st Annual Healthcare Virtual Conference TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/10/21 02/10 04:55 02/10/21 04:55 ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) , AVRO Avrobio $17.68 / -1.62 (-8.39%) , BMRN BioMarin $85.63 / -0.55 (-0.64%) , DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) , FIXX Homology Medicines $14.38 / -0.39 (-2.64%) , FOLD Amicus $19.18 / -0.7 (-3.52%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $52.55 / +1.74 (+3.42%) , ORPH Orphazyme $13.07 / + (+0.00%) , ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) , PASG Passage Bio $20.12 / -0.57 (-2.75%) , PFE Pfizer $34.96 / +0.14 (+0.40%) , RARE Ultragenyx $167.72 / +1.9 (+1.15%) , SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) , SNY Sanofi $48.87 / +0.275 (+0.57%) , TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) , TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $48.87 / +0.275 (+0.57%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $167.72 / +1.9 (+1.15%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M PFE Pfizer $34.96 / +0.14 (+0.40%) 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses PASG Passage Bio $20.12 / -0.57 (-2.75%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $13.07 / + (+0.00%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $52.55 / +1.74 (+3.42%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.18 / -0.7 (-3.52%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $85.63 / -0.55 (-0.64%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $17.68 / -1.62 (-8.39%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $85.63 / -0.55 (-0.64%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright 11/10/20 Goldman Sachs Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs 11/06/20 H.C. Wainwright Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.18 / -0.7 (-3.52%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan 10/28/20 Deutsche Bank Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank NVTA Invitae $52.55 / +1.74 (+3.42%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $13.07 / + (+0.00%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $20.12 / -0.57 (-2.75%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.96 / +0.14 (+0.40%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler RARE Ultragenyx $167.72 / +1.9 (+1.15%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.87 / +0.275 (+0.57%) 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.87 / +0.275 (+0.57%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $167.72 / +1.9 (+1.15%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.96 / +0.14 (+0.40%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $20.12 / -0.57 (-2.75%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $52.55 / +1.74 (+3.42%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.18 / -0.7 (-3.52%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) 08/10/20 Homology Medicines reports Q2 EPS (78c), consensus (76c) DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $85.63 / -0.55 (-0.64%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.87 / +0.275 (+0.57%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.96 / +0.14 (+0.40%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.18 / -0.7 (-3.52%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $85.63 / -0.55 (-0.64%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.87 / +0.275 (+0.57%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.96 / +0.14 (+0.40%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $20.12 / -0.57 (-2.75%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $13.07 / + (+0.00%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $52.55 / +1.74 (+3.42%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.18 / -0.7 (-3.52%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $85.63 / -0.55 (-0.64%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/12/21 17th Annual Virtual WORLDSymposium 2021 02/16/21 Abeona Clinical Investigator Webinar 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.96 / +0.14 (+0.40%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $20.12 / -0.57 (-2.75%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $52.55 / +1.74 (+3.42%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.18 / -0.7 (-3.52%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $85.63 / -0.55 (-0.64%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/09/21 02/09 04:55 02/09/21 04:55 ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) , AVRO Avrobio $19.30 / +2.17 (+12.67%) , BMRN BioMarin $86.19 / +1.18 (+1.39%) , DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) , FIXX Homology Medicines $14.76 / +0.92 (+6.65%) , FOLD Amicus $19.88 / -0.21 (-1.05%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $50.81 / +1.19 (+2.40%) , ORPH Orphazyme $13.07 / +0.57 (+4.56%) , ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) , PASG Passage Bio $20.69 / -0.86 (-3.99%) , PFE Pfizer $34.82 / -0.1 (-0.29%) , RARE Ultragenyx $166.04 / +4.28 (+2.65%) , SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) , SNY Sanofi $48.60 / +0.4 (+0.83%) , TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) , TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine 01/25/21 Nanobiotix to partner with Sanofi on gene therapy pipeline SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $166.04 / +4.28 (+2.65%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M PFE Pfizer $34.82 / -0.1 (-0.29%) 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses PASG Passage Bio $20.69 / -0.86 (-3.99%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN 01/14/21 Orchard Therapeutics granted RMAT designation for OTL-200 ORPH Orphazyme $13.07 / +0.57 (+4.56%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $50.81 / +1.19 (+2.40%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.88 / -0.21 (-1.05%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $86.19 / +1.18 (+1.39%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $19.30 / +2.17 (+12.67%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $86.19 / +1.18 (+1.39%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright 11/10/20 Goldman Sachs Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs 11/06/20 H.C. Wainwright Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.88 / -0.21 (-1.05%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan 10/28/20 Deutsche Bank Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank NVTA Invitae $50.81 / +1.19 (+2.40%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $13.07 / +0.57 (+4.56%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $20.69 / -0.86 (-3.99%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.82 / -0.1 (-0.29%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler RARE Ultragenyx $166.04 / +4.28 (+2.65%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $166.04 / +4.28 (+2.65%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.82 / -0.1 (-0.29%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $20.69 / -0.86 (-3.99%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $50.81 / +1.19 (+2.40%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.88 / -0.21 (-1.05%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) 08/10/20 Homology Medicines reports Q2 EPS (78c), consensus (76c) DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $86.19 / +1.18 (+1.39%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.60 / +0.4 (+0.83%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.82 / -0.1 (-0.29%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.88 / -0.21 (-1.05%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $86.19 / +1.18 (+1.39%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.60 / +0.4 (+0.83%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.82 / -0.1 (-0.29%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $20.69 / -0.86 (-3.99%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $13.07 / +0.57 (+4.56%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $50.81 / +1.19 (+2.40%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.88 / -0.21 (-1.05%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $86.19 / +1.18 (+1.39%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/12/21 17th Annual Virtual WORLDSymposium 2021 02/16/21 Abeona Clinical Investigator Webinar 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.82 / -0.1 (-0.29%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $20.69 / -0.86 (-3.99%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $50.81 / +1.19 (+2.40%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.88 / -0.21 (-1.05%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $86.19 / +1.18 (+1.39%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 08:57 02/08/21 02/08 08:57 02/08/21 08:57 ABEO Abeona Therapeutics $2.59 / +0.13 (+5.28%) , AVRO Avrobio $17.13 / +1.11 (+6.93%) , BMRN BioMarin $85.26 / +0.62 (+0.73%) , DNLI Denali Therapeutics $70.51 / +0.92 (+1.32%) , FIXX Homology Medicines $13.83 / +0.45 (+3.36%) , FOLD Amicus $20.09 / -0.09 (-0.45%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $49.65 / -0.495 (-0.99%) , ORPH Orphazyme $12.50 / +0.39 (+3.22%) , ORTX Orchard Therapeutics $7.35 / +1.155 (+18.64%) , PASG Passage Bio $21.49 / -0.41 (-1.87%) , PFE Pfizer $34.92 / +0.03 (+0.09%) , RARE Ultragenyx $161.76 / +7.21 (+4.67%) , SGTX Sigilon Therapeutics $34.25 / -0.35 (-1.01%) , SNY Sanofi $48.19 / +1.11 (+2.36%) , TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) , TVTX Travere Therapeutics $31.81 / +0.29 (+0.92%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.81 / +0.29 (+0.92%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $48.19 / +1.11 (+2.36%) 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine 01/25/21 Nanobiotix to partner with Sanofi on gene therapy pipeline SGTX Sigilon Therapeutics $34.25 / -0.35 (-1.01%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $161.76 / +7.21 (+4.67%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M PFE Pfizer $34.92 / +0.03 (+0.09%) 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses PASG Passage Bio $21.49 / -0.41 (-1.87%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $7.35 / +1.155 (+18.64%) 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN 01/14/21 Orchard Therapeutics granted RMAT designation for OTL-200 ORPH Orphazyme $12.50 / +0.39 (+3.22%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $49.65 / -0.495 (-0.99%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $20.09 / -0.09 (-0.45%) 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities 01/11/21 Amicus sees 2021 Galafold revenue of at least $300M 01/11/21 Amicus sees Q4 Galafold revenue $70M FIXX Homology Medicines $13.83 / +0.45 (+3.36%) 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer 11/19/20 Pfizer reports 9.9% passive stake in Homology Medicines DNLI Denali Therapeutics $70.51 / +0.92 (+1.32%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $85.26 / +0.62 (+0.73%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $17.13 / +1.11 (+6.93%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $2.59 / +0.13 (+5.28%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $2.59 / +0.13 (+5.28%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $17.13 / +1.11 (+6.93%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $85.26 / +0.62 (+0.73%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $70.51 / +0.92 (+1.32%) 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright 11/10/20 Goldman Sachs Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs 11/06/20 H.C. Wainwright Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright FIXX Homology Medicines $13.83 / +0.45 (+3.36%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $20.09 / -0.09 (-0.45%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan 10/28/20 Deutsche Bank Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank 07/27/20 Morgan Stanley Idorsia initiated with an Equal Weight at Morgan Stanley NVTA Invitae $49.65 / -0.495 (-0.99%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $12.50 / +0.39 (+3.22%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $7.35 / +1.155 (+18.64%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $21.49 / -0.41 (-1.87%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.92 / +0.03 (+0.09%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler RARE Ultragenyx $161.76 / +7.21 (+4.67%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $34.25 / -0.35 (-1.01%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.19 / +1.11 (+2.36%) 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $31.81 / +0.29 (+0.92%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.81 / +0.29 (+0.92%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.19 / +1.11 (+2.36%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $161.76 / +7.21 (+4.67%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.92 / +0.03 (+0.09%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $21.49 / -0.41 (-1.87%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $7.35 / +1.155 (+18.64%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $49.65 / -0.495 (-0.99%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $20.09 / -0.09 (-0.45%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) FIXX Homology Medicines $13.83 / +0.45 (+3.36%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) 08/10/20 Homology Medicines reports Q2 EPS (78c), consensus (76c) DNLI Denali Therapeutics $70.51 / +0.92 (+1.32%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $85.26 / +0.62 (+0.73%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $17.13 / +1.11 (+6.93%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $2.59 / +0.13 (+5.28%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.19 / +1.11 (+2.36%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.92 / +0.03 (+0.09%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $20.09 / -0.09 (-0.45%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $85.26 / +0.62 (+0.73%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.19 / +1.11 (+2.36%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $34.25 / -0.35 (-1.01%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.92 / +0.03 (+0.09%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $21.49 / -0.41 (-1.87%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $12.50 / +0.39 (+3.22%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $49.65 / -0.495 (-0.99%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $20.09 / -0.09 (-0.45%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $70.51 / +0.92 (+1.32%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $85.26 / +0.62 (+0.73%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $17.13 / +1.11 (+6.93%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/12/21 17th Annual Virtual WORLDSymposium 2021 02/16/21 Abeona Clinical Investigator Webinar 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $31.81 / +0.29 (+0.92%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.19 / -0.005 (-0.03%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.92 / +0.03 (+0.09%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $21.49 / -0.41 (-1.87%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $49.65 / -0.495 (-0.99%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $20.09 / -0.09 (-0.45%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $85.26 / +0.62 (+0.73%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	European Association for Hemophilia & Allied Disorders to hold conference » 04:55 02/05/21 02/05 04:55 02/05/21 04:55 BAYRY Bayer $0.00 / + (+0.00%) , BMRN BioMarin $84.69 / +1.72 (+2.07%) , NVO Novo Nordisk $71.66 / -0.78 (-1.08%) , PFE Pfizer $34.88 / +0.04 (+0.11%) , SNY Sanofi $47.09 / +0.23 (+0.49%) , TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) EAHAD 2021 Virtual… EAHAD 2021 Virtual Congress will be held on February 2-5. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TAK SNY PFE NVO BMRN BAYRY TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $47.09 / +0.23 (+0.49%) 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine 01/25/21 Nanobiotix to partner with Sanofi on gene therapy pipeline 01/12/21 Sanofi says IPO on Euronext Paris for European API company evaluated for 2022 PFE Pfizer $34.88 / +0.04 (+0.11%) 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses 02/01/21 BioNTech, Pfizer boosts 2021 Covid vaccine plans to 2B doses from 1.3B 02/01/21 BioNTech, Pfizer plan to manufacture 2B doses of Covid vaccine in 2021 NVO Novo Nordisk $71.66 / -0.78 (-1.08%) 02/03/21 Novo Nordisk chief scientific officer Thomsen to retire 01/29/21 Novo Nordisk announces positive opinion from CHMP for once-weekly Sogroya 01/29/21 Novo Nordisk's Sogroya gets positive recommendation from EMA's CHMP 01/20/21 Novo Nordisk seeks FDA approval for new Ozempic dose BMRN BioMarin $84.69 / +1.72 (+2.07%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies BAYRY Bayer $0.00 / + (+0.00%) 02/03/21 Bayer announes $2B agreement to resolve future Roundup cases 01/26/21 Kronos Bio appoints Marianne De Backer to board of directors 01/08/21 Argenx expects 2021 cash burn 'approximately doubling' compared to 2020 01/08/21 Bayer says FDA approves addition of OS and other data to Nubeqa prescribing info BAYRY BMRN NVO PFE SNY TAK BAYRY Bayer $0.00 / + (+0.00%) 02/04/21 Citi opens positive 'Catalyst Watch' on Bayer 01/27/21 Deutsche Bank Bayer price target raised to EUR 63 from EUR 62 at Deutsche Bank 01/20/21 Credit Suisse Bayer price target raised to EUR 55 from EUR 47 at Credit Suisse 01/08/21 Morgan Stanley Bayer price target lowered to EUR 66 from EUR 67 at Morgan Stanley BMRN BioMarin $84.69 / +1.72 (+2.07%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan NVO Novo Nordisk $71.66 / -0.78 (-1.08%) 02/04/21 Barclays Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays 01/20/21 Citi Citi opens 'Positive Catalyst Watch' on Novo Nordisk 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse 01/20/21 Credit Suisse Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse PFE Pfizer $34.88 / +0.04 (+0.11%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler SNY Sanofi $47.09 / +0.23 (+0.49%) 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley 01/08/21 Morgan Stanley Roche downgraded to Equal Weight from Overweight at Morgan Stanley TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital SNY PFE NVO BMRN BAYRY SNY Sanofi $47.09 / +0.23 (+0.49%) 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year PFE Pfizer $34.88 / +0.04 (+0.11%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open NVO Novo Nordisk $71.66 / -0.78 (-1.08%) 02/03/21 Novo Nordisk sees FY21 sales growth up 5%-9%, operating profit up 4%-8% 02/03/21 Novo Nordisk report FY20 EPS DKK 18.01 vs. DKK 16.38 last year 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% BMRN BioMarin $84.69 / +1.72 (+2.07%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 BAYRY Bayer $0.00 / + (+0.00%) 11/03/20 Bayer confirms FY20 targets, sees core EPS EUR6.70-EUR6.90 11/03/20 Bayer reports Q3 core EPS down 30.2% to EUR0.81 09/30/20 Bayer confirms 2020 adjusted view, sees 2021 core EPS 'slightly' down from 2020 09/30/20 Bayer expects 2021 sales at approximately 2020 levels TAK SNY PFE BMRN BAYRY TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $47.09 / +0.23 (+0.49%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.88 / +0.04 (+0.11%) 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says 01/25/21 Pfizer to ship fewer vaccine vials to fulfill commitment to U.S., NY Times says BMRN BioMarin $84.69 / +1.72 (+2.07%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets BAYRY Bayer $0.00 / + (+0.00%) 01/06/21 CureVac, Bayer reach alliance deal over COVID-19 vaccine, Reuters says 10/27/20 EPA clears use of Bayer's XtendiMax for five years, Reuters reports 10/11/20 Bayer, BASF fighting to keep weedkiller on U.S. farms, WSJ reports 09/15/20 Bayer resolves thousands of U.S. Roundup cases with trial lawyers, Reuters says TAK SNY PFE NVO BMRN BAYRY TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $47.09 / +0.23 (+0.49%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday PFE Pfizer $34.88 / +0.04 (+0.11%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday NVO Novo Nordisk $71.66 / -0.78 (-1.08%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication BMRN BioMarin $84.69 / +1.72 (+2.07%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street BAYRY Bayer $0.00 / + (+0.00%) 01/07/21 Fly Intel: Pre-market Movers 09/30/20 Fly Intel: Wall Street's top stories for Wednesday 09/29/20 Fly Intel: Wall Street's top stories for Tuesday 08/20/20 Fly Intel: Wall Street's top stories for Thursday 02/02/21 EAHAD 2021 Virtual Congress 02/12/21 17th Annual Virtual WORLDSymposium 2021 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/05/21 Sanofi - SNY 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 TAK PFE NVO BMRN TAK Takeda Pharmaceutical $17.19 / -0.235 (-1.35%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.88 / +0.04 (+0.11%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th NVO Novo Nordisk $71.66 / -0.78 (-1.08%) 12/16/20 Unusually active option classes on open December 16th BMRN BioMarin $84.69 / +1.72 (+2.07%) 09/18/20 BioMarin call volume above normal and directionally bullish

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial